None listed
Conditions
Interventions
Intervention1: COVISHIELD: COVISHIELD: ChAdOx1 nCoV-19 Corona Virus Vaccine
(Recombinant).
Intervention2: BBV154: BBV154: Replication deficient Adenoviral vector-based (expressing a
stabilized spike
Sponsors
Bharat Biotech International Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1. Ability to provide written informed consent. 2. Participants of either gender of age =18 years. 3. Received and completed Coronavirus Disease 2019 vaccine under Emergency Use Authorization (EUA) dosing guidelines at least 6 ± 1month (after receipt of second dose of EUA vaccine) prior to enrollment, confirmed by the electronic Covid-19 Certificate (CoWIN). 4. Expressed interest and availability to fulfill the study requirements. 5. For a female participant of child-bearing potential, planning to avoid becoming pregnant (use of an effective method of contraception or abstinence) from the time of study enrolment until at least four weeks after vaccination 6. Agrees not to participate in another clinical trial at any time during the study period. 7. Agrees to remain in the study area for the entire duration of the study. 8. Willing to allow storage and future use of biological samples for future research
Exclusion criteria
Exclusion criteria: 1. Known history of COVID-19 infection. 2. For women of child bearing potential, a positive serum pregnancy test (during screening within 45 days of enrolment) or positive urine pregnancy test (within 24 hours of administering vaccine). 3. Temperature >38.0°C (100.4°F) or symptoms of an acute self limiting illness such as an upper respiratory infection or gastroenteritis within three days prior to vaccination. 4. Medical problems because of alcohol or illicit drug use during the past 12 months. 5. Receipt of an experimental agent (vaccine, drug, device, etc.) within 60 days before enrolment or expects to receive an investigational agent during the study period. 6. Receipt of any licensed vaccine within four weeks before enrolment in this study. 7. Known sensitivity to any ingredient of the study vaccines, or a more severe allergic reaction and history of allergies in the past. 8. Receipt of immunoglobulin or other blood products within the three months prior to vaccination in this study. 9. Immunosuppression because of an underlying illness or treatment with immunosuppressive or cytotoxic drugs or use of anticancer chemotherapy or radiation therapy within the preceding 36 months. 10. Long-term use ( > 2 weeks) of oral or parenteral steroids (glucocorticoids) or high-dose inhaled steroids ( >800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding six months (nasal and topical steroids are allowed). 11. Any history of anaphylaxis in relation to vaccination. 12. History of any cancer. 13. History of severe psychiatric conditions likely to affect participation in the study. 14. A bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder, or prior history of significant bleeding or bruising following IM injections or venepuncture). 15. Any other serious chronic illness requiring immediate hospital specialist supervision. 16. Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| 1. GMTs of serum IgG, IgA Abs by ELISA. 2. Vaccine induced T and B cell responses. 3. GMTs of secretary IgA Abs by ELISA. 4.The occurrence of solicited adverse events 5. The occurrence of serious adverse events (SAEs) and unsolicited AEs 6. The occurrence of adverse event of special interest (AESI). Timepoint: 1. Day 0 , 28 and 56 2. Day 0 , 28 and 56 3. Day 0 , 28 and 56 4. 7 days 5. Through out the study | — |
Primary
| Measure | Time frame |
|---|---|
| 1. Geometric mean titres (GMTs) of serum neutralising antibody titer (NAb’s) by Neutralising Antibody Assays Timepoint: 1. Day 0 , 28 and 56 | — |
Countries
India
Contacts
Public ContactDr Krishna Mohan
Bharat Biotech International Ltd
Outcome results
None listed